GlassScriptPhysician profile
Jasmine Thuy Nguyen
NPI 1851735641
$8,720.08
in general payments reported to CMS, 2019-2025
11 companies · $4,640 in 2025
The $4,640 reported for 2025 was more than what 99% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $893 · 2020: $116 · 2021: $312 · 2022: $656 · 2023: $1,392 · 2024: $712 · 2025: $4,640.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,158 · Travel and Lodging: $586.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,157.78 |
| Travel and Lodging | $586.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lumenis Be INC | $4,653.65 | 2023-2025 | Optilight, M22 |
| Coopervision INC. | $1,616.70 | 2019-2025 | Cvi Contact Lens, Myday Contact Lens, Biofinity Contact Lens |
| Alcon Vision LLC | $650.42 | 2019-2025 | Precision7, Total30, Precision 1 |
| Johnson & Johnson Vision Care, INC. | $577.00 | 2019-2024 | Acuvue |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $488.77 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $231.64 | 2022-2025 | Infuse |
| Tarsus Pharmaceuticals, INC. | $166.42 | 2025 | Xdemvy |
| Glaukos Corporation | $160.81 | 2023 | Photrexa Cross-Linking Kit |
| Apellis Pharmaceuticals, INC. | $119.34 | 2024 | Syfovre |
| Visionix USA, INC | $38.09 | 2022 | |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jasmine Nguyen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.